Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ACACA | Q13085 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256334 | 0.90 | ACACB (1.00) | ACACBALDH1A1LMNA | |
| SCHEMBL12001318 | 0.84 | ACACB (0.83) | ACACBALDH1A1LMNAACACAL3MBTL1 | |
| SCHEMBL12001074 | 0.81 | ACACB (0.80) | ACACBALDH1A1ACACAPLK1GAA | |
| SCHEMBL21160945 | 0.79 | ACACB (0.59) | ACACBALDH1A1LMNAL3MBTL1 | |
| SCHEMBL16341200 | 0.78 | ACACB (0.60) | ACACBL3MBTL1 | |
| SCHEMBL564817 | 0.76 | ACACB (0.57) | ACACBALDH1A1L3MBTL1PLK1 | |
| SCHEMBL29675650 | 0.76 | ACACB (0.86) | ACACBALDH1A1ACACAL3MBTL1PLK1 | |
| SCHEMBL22066521 | 0.75 | LMNA (0.55) | ACACBALDH1A1LMNAACACAL3MBTL1 | |
| SCHEMBL14951697 | 0.75 | ACACB (0.57) | ACACBALDH1A1LMNAL3MBTL1PLK1 | |
| SCHEMBL12001375 | 0.75 | ACACB (0.80) | ACACBALDH1A1LMNAACACAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885ALDH1A1 1739/4885LMNA 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.